Last reviewed: June 2, 2026
Vigil Neuroscience
VGL101 (iluzanebart)
TargetTREM2
Modalitymonoclonal antibody (TREM2 agonist)
IndicationAdult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)
PhasePhase 2 (Terminated)
Trial IDNCT05677659
Notes
IGNITE trial. Iluzanebart is a monoclonal antibody acting as a TREM2 agonist, designed to compensate for microglial dysfunction in ALSP (an underlying disease caused by CSF1R mutations).
Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.
Last reviewed: June 2, 2026